Developer docs
API playgroundTry for free, no card

Search company profiles

BioMotiv

Full company profile

uuid0008xna

Namestring
BioMotiv
Websiteurl
biomotiv.com
Company typeenum
Private
Founded yearint
2012
Short descriptiontext

BioMotiv is a Cleveland-based therapeutic accelerator, founded in 2012, that builds and funds a portfolio of novel medicines sourced from academic and institutional partners, serving as a development intermediary between early-stage science and pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
therapeutic accelerator, drug development, biopharmaceutical development, novel medicines, clinical translation
Industry2 codes
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical Drug Development
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioMotiv is a therapeutic accelerator that identifies, in-licenses, de-risks, and advances a portfolio of novel therapeutic candidates from academic and early-stage sources toward clinical development. The company funds and manages drug development programs across multiple therapeutic areas, leveraging partnerships with biopharmaceutical companies, academic medical centers, and patient foundations.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Therapeutic Accelerator Program
No data
Peers8 records
1Cydan Development
TypeDirect peer
Description

Accelerator focused on identifying and de-risking therapeutic candidates for rare diseases, spinning out NewCos around validated assets — same accelerator/venture-creation playbook as BioMotiv.

TypeBroad incumbent
Description

Large biotech creation engine that conceives, launches, and operates multiple therapeutic platform companies — a more established, broader incumbent operating in the same therapeutic-acceleration space as BioMotiv.

TypeDirect peer
Description

Venture firm that builds biotech companies from inception around early-stage therapeutic programs, often via in-house translation. Comparable to BioMotiv as a competing model for early drug-discovery capital.

4Bridge Medicines
TypeDirect peer
Description

Drug-development accelerator created by Memorial Sloan Kettering, Rockefeller, and Weill Cornell that in-licenses early-stage discoveries and advances them toward IND — directly comparable to BioMotiv's therapeutic accelerator model.

TypeBroad incumbent
Description

Healthcare-focused investment firm with dedicated therapeutic-company creation capabilities and academic-partnership programs; competes with BioMotiv for translational-stage deals and academic licenses.

TypeDirect peer
Description

Early-stage biotech investment and operating platform that incubates and builds therapeutic companies, directly competing for translational-stage assets and partnerships.

TypeOthers
Description

Comparable model of academic-medical-center-anchored translational drug-development partnerships that serve as feedstock sources for accelerators like BioMotiv.

TypeOthers
Description

Federal translational-science entity that funds and operates therapeutic development programs; serves as an ecosystem participant influencing deal flow, funding, and competition for translational-stage assets comparable to BioMotiv's pipeline.

Market position
Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioMotiv

Biopharmaceutical Drug Developmentbiomotiv.com

BioMotiv is a Cleveland-based therapeutic accelerator, founded in 2012, that builds and funds a portfolio of novel medicines sourced from academic and institutional partners, serving as a development intermediary between early-stage science and pharmaceutical partners.

BioMotiv firmographics

Firmographics
Name
BioMotiv
Website
https://biomotiv.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
BioMotiv is a Cleveland-based therapeutic accelerator, founded in 2012, that builds and funds a portfolio of novel medicines sourced from academic and institutional partners, serving as a development intermediary between early-stage science and pharmaceutical partners.
Ownership category
akta.pro rank

BioMotiv industry classification

Industry
Product category
Biopharmaceutical Drug Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Therapeutic accelerator
  • Drug development
  • Biopharmaceutical development
  • Novel medicines
  • Clinical translation

Where BioMotiv is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Markets served

BioMotiv business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

BioMotiv product offering

Product offering

Core offering

BioMotiv is a therapeutic accelerator that identifies, in-licenses, de-risks, and advances a portfolio of novel therapeutic candidates from academic and early-stage sources toward clinical development. The company funds and manages drug development programs across multiple therapeutic areas, leveraging partnerships with biopharmaceutical companies, academic medical centers, and patient foundations.

Differentiator

Problem solved

Functional benefit

Products and services

  • Therapeutic Accelerator Program

Companies that use BioMotiv

Customer profile

Ideal customer profiles2 records

BioMotiv technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BioMotiv competitors and assessment

Company assessment

Direct peers

  • Cydan Development: Accelerator focused on identifying and de-risking therapeutic candidates for rare diseases, spinning out NewCos around validated assets — same accelerator/venture-creation playbook as BioMotiv.
  • Atlas Venture: Venture firm that builds biotech companies from inception around early-stage therapeutic programs, often via in-house translation. Comparable to BioMotiv as a competing model for early drug-discovery capital.
  • Bridge Medicines: Drug-development accelerator created by Memorial Sloan Kettering, Rockefeller, and Weill Cornell that in-licenses early-stage discoveries and advances them toward IND — directly comparable to BioMotiv's therapeutic accelerator model.
  • Accelerator Life Science Partners: Early-stage biotech investment and operating platform that incubates and builds therapeutic companies, directly competing for translational-stage assets and partnerships.

Broad incumbents

  • Flagship Pioneering: Large biotech creation engine that conceives, launches, and operates multiple therapeutic platform companies — a more established, broader incumbent operating in the same therapeutic-acceleration space as BioMotiv.
  • Deerfield Management: Healthcare-focused investment firm with dedicated therapeutic-company creation capabilities and academic-partnership programs; competes with BioMotiv for translational-stage deals and academic licenses.

Others

Market position

Customer concentration

BioMotiv social profiles

Digital presence

BioMotiv financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioMotiv leadership team

Management profile

Number of profiles

Profiles4 records

BioMotiv funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioMotiv M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioMotiv

What does BioMotiv do?

BioMotiv is a therapeutic accelerator that identifies, in-licenses, de-risks, and advances a portfolio of novel therapeutic candidates from academic and early-stage sources toward clinical development. The company funds and manages drug development programs across multiple therapeutic areas, leveraging partnerships with biopharmaceutical companies, academic medical centers, and patient foundations.

When was BioMotiv founded?

BioMotiv was founded in 2012. It employs 1 to 10 people.

Where is BioMotiv based?

BioMotiv is headquartered in Cleveland, United States, in the North America region.

Who are BioMotiv's main competitors?

Direct peers on record are Cydan Development, Atlas Venture, Bridge Medicines and Accelerator Life Science Partners. Broad incumbents are Flagship Pioneering and Deerfield Management. Others are Indiana University School of Medicine / AMPATH Health (illustrative academic partner) and National Institutes of Health (NCATS).

Does BioMotiv have an API?

No public API is recorded for BioMotiv.

What industry is BioMotiv in?

BioMotiv's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SynBioBetaBioMotiv and Atomwise Sign AI Partnership to Transform Therapeutic DevelopmentBioMotiv and Atomwise announced a strategic collaboration on January 13, 2020, to co-develop therapies using artificial intelligence for small molecule discovery. The partnership will form joint development companies to integrate Atomwise's AI technology with BioMotiv's drug development expertise, aiming to accelerate the commercialization of early-stage research. The collaboration seeks to bridge gaps in the drug development process by enabling the pursuit of challenging drug targets and reducing costs associated with traditional methods.Business Wire BlogBioMotiv and Atomwise Sign AI Partnership to Transform Therapeutic DevelopmentBioMotiv and Atomwise announced a strategic collaboration to co-develop therapies, forming joint development companies that integrate Atomwise's AI technology with BioMotiv's drug development expertise. The partnership aims to translate early-stage research into small molecule therapies, with Atomwise's AI screening ultra-large compound libraries to reduce testing costs and time.FierceBiotechBristol-Myers teams with BioMotiv to build and buy biotechsBristol-Myers Squibb has allied with biotech accelerator BioMotiv to found and fund biotechs, acquiring them after preclinical candidates are identified. The deal makes Bristol-Myers a limited partner, with potential acquisitions at pre-agreed terms. This follows a 2015 partnership with Dual Therapeutics, which later fell off the radar.NewswireA New Research Partnership to Find Treatments for Neurological DisordersBioMotiv and Cure Network Dolby Acceleration Partners signed an agreement to develop small molecules targeting inhibitory interneurons for neurological disorders. The partnership builds on Gladstone's research showing that enhancing interneuron function improves cognitive function in Alzheimer's models. The collaboration aims to suppress epileptic activity and improve cognitive abnormalities in conditions like Alzheimer's, epilepsy, autism, and schizophrenia.PR NewswireLife sciences startup receives significant funding for developing novel therapeutics for respiratory diseasesAllinaire Therapeutics LLC, a life sciences startup developing novel therapeutics for pulmonary diseases including COPD and AAT deficiency, has received new investments from BioCrossroads' Indiana Seed Fund II, BioMotiv, and Indiana University's Innovate Indiana Fund. The funding will advance the development of therapeutics based on discoveries by researchers from Indiana University School of Medicine and National Jewish Health, who found that symptoms of these respiratory diseases can be mitigated by reducing the activity of certain secreted proteins. The company previously received grant support from the National Institutes of Health Small Business Innovation & Research program.MedCity NewsBioMotiv announces new startup: Anti-cancer drug developer Z53 TherapeuticsBioMotiv announced Z53 Therapeutics, a startup developing drugs for cancer tumors with p53 protein mutations. The company's zinc metallochaperones restore zinc binding in mutant p53, a novel anti-cancer approach. The drugs were developed by Rutgers and SUNY Upstate researchers.PrwebBaruch S. Blumberg Institute to Host 15th Annual Regional Biotech ConferenceThe Baruch S. Blumberg Institute will host its 15th Annual Regional Biotech Conference on November 6, 2015, in Doylestown, Pennsylvania. The event, themed 'Decreasing the Cost of Drug Development,' will feature over 100 life science leaders and cost $75 for registration.FinSMEsBioMotiv Increases Capital to $46MBioMotiv, a Cleveland-based drug development accelerator, increased its total capital to $46M. Backers included Nationwide Mutual Insurance Company and individual investors, with Nationwide appointing a representative to the Board of Managers. The company, led by CEO Baiju R. Shah, seeks early-stage therapeutic technologies.VC News DailyBioMotiv Secures $25M in Additional CapitalBioMotiv, a Cleveland-based drug development company, has secured an additional $25 million in funding, increasing its total capital to $46 million. The funding was supported by local institutions and investors, including Nationwide Mutual Insurance Company, and it aims to develop early-stage therapeutic technologies.